Science

KRAS Mutation Status and Treatment Outcomes in Patients with Metastatic Pancreatic Adenocarcinoma

Metastatic pancreatic cancer/onco-hema.healthbooktimes.org

Jan 19, 2025, 13:39

KRAS Mutation Status and Treatment Outcomes in Patients with Metastatic Pancreatic Adenocarcinoma

Erman Akkus, Medical Oncology Fellow at Ankara University, shared an article by Carter Norton on X:

“KRAS mutations and metastatic pancreatic cancer.

Further evidence supporting KRAS mutation type matters.
G12D, G12V.
G12R

KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma.

Authors: Carter Norton, et al.

KRAS Mutation Status and Treatment Outcomes in Patients with Metastatic Pancreatic Adenocarcinoma

Erman Akkus is a Medical Oncology Fellow at Ankara University, Faculty of Medicine. Previously, he was an Internal Medicine Resident at the Ankara University, Faculty of Medicine. He was also a Visiting Researcher at the University of Oslo. He completed his education at the Medical University of Vienna.

Ankara University cancer Carter Norton fight against cancer Global fight against cancer KRAS mutations Metastatic Pancreatic Adenocarcinoma OncoDaily Oncology Pancreatic Cancer

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success